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AbstrAct
There is evidence demonstrating that sexual complaints represent the most specific symptoms 
associated with late onset hypogonadism, while central obesity is the most specific sign. In obese 
men, hypogonadism can further worsen the metabolic profile and increase abdominal fat. In 
addition, although hypogonadism can exacerbate obesity-associated erectile dysfunction (ED), 
recent data suggest that a direct contribution of fat-derived factors could be hypothesized. 
In particular, an animal model recently documented that fat accumulation induces several 
hepatic pro-inflammatory genes closely linked to corpora cavernosa endothelial dysfunction. 
Lifestyle modifications and weight loss are the first steps in the treatment of ED patients with 
obesity or metabolic diseases. In symptomatic hypogonadal men with metabolic impairment 
and obesity, combining the effect of testosterone substitution with lifestyle modifications could 
result in better outcomes.
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InTroDucTIon
Several population-based surveys have documented 
that in men testosterone (T) levels progressively decline 
with age.1-5 In particular, according to the European 
Male Aging Study (EMAS), a survey of more than 
3400 community-dwelling, middle-aged and older 
men, after the third decade T decreases by 0.4–2% 
per year.5 The specific mechanisms underlying this 
phenomenon have not been completely clarified but 
age-related associated morbidities rather than aging 
per se seem to play a major role.5,6 
Different T thresholds have been proposed for 
the biochemical definition of low T7,8 in aging men, 
also known as late onset hypogonadism (LOH). The 
most widely shared consensus7,8 is that T substitution 
may be beneficial when circulating total T is below 
8 nmol/L (231 ng/dL) in two measurements. More-
over, there is also general agreement that a total T 
level above 12 nmol/L (346 ng/dL) does not require 
substitution. There is in addition a consensus that a 
reduction of T is not sufficient to define a clinically 
relevant hypogonadal state, especially in the “gray 
area”, with circulating T between 8 and 12 nmol/L.7,8 
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Hence, to define LOH, specific hypogonadism-related 
symptoms and signs should also be present.7-10 Data 
from the EMAS survey clearly demonstrated that 
sexual symptoms, in particular low libido and reduced 
spontaneous and sex-related erections, represent the 
most specific symptoms associated with low T (total 
T level of less than 11 nmol/L and a free T (FT) level 
of less than 0.225 nmol/L).11
In line with this evidence, in male subjects consult-
ing for sexual dysfunction, in contrast to other forms 
of male hypogonadism, LOH is a relatively common 
condition. Figure 1 shows the prevalence of symp-
tomatic LOH in the general population of Florence, 
one of the participating centers in the EMAS survey, 
according to age intervals. By using the strict EMAS 
criteria, the prevalence of LOH in Florence increases 
from being quite an unusual condition in the younger 
age groups to more than 3% in the oldest one. In 
the same figure, using the same diagnostic criteria, 
the prevalence of LOH in subjects seeking medical 
care at an andrology unit for sexual dysfunction at 
the University of Florence (UnIFI) - hence from the 
same geographic area - is reported. It is evident that in 
subjects complaining of sexual dysfunction LOH is 5 
times more prevalent than in the general population. 
A large body of evidence has demonstrated that 
although sexual complaints represent the most specific 
symptoms associated with LOH, central obesity is the 
most specific sign.7,8,12-14 Obesity (and in particular 
central obesity-related complications) is also a well-
recognized risk factor for erectile dysfunction.15,16 
Although obesity related metabolic and cardiovascular 
(CV) complications have been proposed as playing 
a major pathogenetic role, recent studies have also 
suggested a direct contribution of several visceral 
fat-derived factors including chemokines, cytokines 
and hormones in the pathogenesis of ED17 (see for 
review 15,16).
In this review, we will analyze in depth the rela-
tionship between obesity, its metabolic complications 
and male hypogonadism (HG), and their contribution 
to the pathogenesis of ED.
METaboLIc IMpaIrMEnT  
anD hypogonaDIsM: a bIDIrEcTIonaL 
LInK conTrIbuTIng To ED 
Clinical evidence
The association between LOH, obesity, metabolic 
syndrome (MetS), insulin resistance and type 2 diabetes 
(T2DM) is well known.7,8,14,18,19 In two independent 
meta-analyses of the available evidence, we have 
reported that subjects with MetS and T2DM have sig-
nificantly reduced T levels (about 3 nmol/l lower).21,22 
These data were more recently confirmed in subjects 
with MetS by Brand et al23 and Zumoff et al,24 and we 
ourselves25 previously showed an inverse correlation 
between body mass index (BMI) and both total and 
free T. In addition, this feature was not associated 
with an adequate increase in luteinizing hormone 
(LH) levels, suggesting the presence of obesity-related 
pituitary impairment response (Figure 2). In accord 
with this data morbidly obese men indicate that LH 
levels and pulse amplitude were attenuated when 
compared to normal weight controls.26,27 Similarly, 
a recent study indicates that in subjects with T2DM 
there is a decreased gonadotropin-releasing hormone 
(GnrH) pulsatility without significant change in 
pituitary sensitivity to GnrH or in testis sensitivity 
to human chorionic gonadotropin.28
Longitudinal analysis of data suggested, however, 
the presence of a bidirectional link between obesity 
and low T. In fact, although low T at baseline increased 
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Figure 1. Prevalence of hypogonadism according to the Euro-
pean Male Aging Study (EMAS) criteria (11) in Florentine sub-
jects of the EMAS survey (n=433) and in a consecutive series 
of (n=3293) output-patients receiving medical care for sexual 
dysfunction between 2000-2011 at our center (UnIFI study; 10). 
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of central obesity in the pathogenies of ED. In line 
with this hypothesis, we previously reported that the 
association between ED and central obesity was inde-
pendent of known obesity-associated comorbidities 
(including hypogonadism) and was more strongly 
linked to an organic than to psychological and rela-
tional problems.15 Similar results were reported by 
the EMAS survey.31 Longitudinal data confirmed 
that obesity and central obesity at baseline were the 
most important predictors for the development of 
secondary hypogonadism at follow up.31 However, 
incident secondary hypogonadism was associated, 
independently of BMI, comorbidities and lifestyle, 
with new or worsening sexual symptoms but not 
physical or psychological ones.31
Preclinical evidence
The specific pathogenetic mechanisms linking LOH 
with obesity and metabolic derangements appear to 
be complex and are not as yet completely understood 
(Figure 2). The presence of a hypothalamus-pituitary 
pathway impairment seems to represent the key fea-
ture. Several adipokines (e.g. leptin), cytokines (e.g. 
tumor necrosis factor-α; TnFα) and gastrointestinal 
hormones (e.g. ghrelin), along with increased estrogen 
the risk of T2DM and MetS at follow up21-23 the op-
posite phenomenon has also been documented.14,18 
Similarly, longitudinal data from the EMAS survey 
showed that weight gain was progressively associ-
ated with a decline in T levels, whereas weight loss 
was proportionately associated with increases in T.29
By comparing the prevalence of endocrine ab-
normalities in two different cohorts from the general 
(Florentine spin-off of the EMAS cohort; n = 202) 
and the symptomatic populations of Florence (a se-
ries of n=3847 patients attending our clinic for ED; 
UnIFI cohort), we recently reported that secondary 
hypogonadism as well as central obesity (waist >102 
cm), impaired fasting glucose (IFG) and T2DM were 
more often detected in UnIFI patients when compared 
to the EMAS cohort.30 Hence, our data confirm that 
ED populations represent a cohort of subjects with 
increased incidence of metabolic abnormalities and 
hypogonadism. It is conceivable that central obesity-
associated hypogonadism might partially justify this 
association. However, our analyses indicated that the 
association between central obesity and ED in the 
UnIFI cohort was confirmed even after the adjust-
ment for T levels and BMI, suggesting a direct role 
Figure 2. Proposed interactions between increased visceral fat and hypogonadism. MetS: metabolic syndrome; T2DM: type 2 diabetes 
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production by the expanded fat deposits, have been 
suggested as causing the gonadotropin failure.14,32-34 
One of the most intriguing working hypotheses is 
related to the role played by estrogens (Figure 2). 
The increased estrogen levels, which characterize 
obesity, might in turn have a negative effect on both 
the hypothalamus and the pituitary, leading to de-
creased LH secretion.14,32-34 Accordingly, the use of 
the aromatase inhibitor letrozole can restore T levels 
and increase LH levels in severely obese hypogonadal 
men.35 Similarly, body weight loss, obtained through 
either lifestyle or bariatric intervention, is associated 
with a fall in estrogen levels and with a rise in go-
nadotropins and T.36 However, the role of estrogens 
in reducing GnrH-gonadotropin secretion has not 
been confirmed in obese diabetic23 and non-diabetic 
men.6 Hence, besides estrogens, other fat-associated 
factors have been proposed as a link between obesity 
and reproductive axis disorders (Figure 2). In fact, 
obesity may cause peripheral and central insulin 
resistance, pro-inflammatory cytokine production 
(TnFα and interleukin-6, IL-6) from adipocytes and 
central nervous system endocannabinoid release that 
can induce down-regulation of hypothalamic func-
tion.14,31 In an animal model of MetS, we previously 
reported that increased visceral fat and the overall 
MetS condition, and in particular the related altered 
glucose and lipid metabolism, were associated with 
hypothalamic inflammation and derangement in the 
neuron network controlling GnrH release.32,33,38 In 
addition, it is possible that peripheral metabolic de-
rangements, such as those clustered in the MetS, signal 
to the hypothalamus via increased local inflammation 
and via a glucose-centered down-regulation of the 
neuronal network controlling GnrH release. In fact, 
recent findings demonstrated that a subpopulation of 
GnrH neurons projects dendrites into regions outside 
the blood brain barrier, where they may directly sense 
molecules circulating in the bloodstream.39 Using a 
well characterized cellular model, we identified a 
direct inhibitory action of increasing glucose con-
centrations on human fetal GnrH-secreting neurons, 
the FnC-B4 cells.32 In line with this hypothesis, we 
recently reported that in subjects with ED almost ¾ 
of cases of the unknown causes of hypogonadism can 
be attributed to metabolic abnormalities including 
obesity and MetS.40
Furthermore, established hypogonadism might 
also worsen obesity. In vitro studies indicate that 
androgens inhibit adipogenic differentiation of mouse 
or human preadipocytes (rPAD) through an androgen 
receptor (Ar)-mediated pathway.41,42 In addition, 
we demonstrated that high-fat-diet (HFD)-induced 
hypogonadism in rabbits determines the impairment 
of several cellular abnormalities in rPAD, including 
a reduced ability of triglyceride synthesis, glucose 
uptake, protein kinase B (AKT) phosphorylation 
and glucose transporter type 4 (GLUT4) membrane 
translocation, as well as by the reduced expression 
of adipogenic genes.43,44
Despite the specific mechanisms linking obesity and 
hypogonadism, our experimental data support the view 
of a direct role of obesity in the pathogenesis of ED. In 
fact, the strong association between visceral adiposity 
and impaired acetylcholine-induced relaxation in the 
corpora cavernosa (CC) was not explained by any 
metabolic or hormonal alteration considered.15 In a 
further study by our group,17 we demonstrated that in 
an animal model diet-induced visceral-fat accumula-
tion was associated with nonalcoholic steatohepatitis 
(nASH) and that several hepatic pro-inflammatory 
genes were closely linked to CC endothelial dysfunc-
tion (acetylcholine responsiveness). In particular, 
we proposed that nASH plays an active role in the 
pathogenesis of ED through TnFα.17
Interventional evidence
Lifestyle modifications
According to all recommendations, lifestyle modi-
fications should be the usual first-line approach for 
all patients. In fact, there is a good deal of evidence 
documenting that in individuals at risk, intensive life-
style interventions, along with nutritional counseling 
and physical activity, are able to reduce weight and 
insulin resistance, thus preventing the progression of 
obesity to other diseases, such as overt diabetes and 
CV disease.45-49
Interestingly, meta-analyzing available evidence, 
we recently demonstrated that weight loss is also able 
to increase T levels proportionately related to the 
amount of reduction in body weight.36 In addition, in 
the same study we observed a weight loss-dependent 
increase in SHBG, calculated FT (cFT), LH and 
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of dietary modification challenges encountered by 
patients with T2DM and/or heart disease reported 
that common challenges in these subjects include self-
discipline, knowledge, coping with everyday stress, 
negotiating with family members and managing the 
social significance of food. This report also confirms 
that despite health care provider recommendations 
encouraging people at risk to change their diet, many 
patients find it difficult to modify what they eat.55
T is an anabolic hormone and its effects on muscle 
growth and function are well known. recently, some 
observational studies in men with LOH reported 
substantial weight loss with T substitution.56-58 Hence, 
the concept of testosterone supplementation (TS) as 
a new anti-obesity medication in men with LOH is 
gaining ground.14,18,59-61 On the other hand, TS is able 
to improve sexual function in hypogonadal (total T 
<12 nM) men.61,62 Therefore, T could be used in as-
sociation with lifestyle intervention in hypogonadal 
men to improve metabolic and sexual outcomes. In 
this section, the metabolic and sexual effects of TS 
will be analyzed in greater detail.
TS and metabolic outcomes 
The anti-obesity activity of TS in hypogonadal 
men may be effective because, on the one hand, it 
reduces abdominal fat accumulation and, on the other, 
it improves muscle mass and strength, facilitating 
adherence to exercise regimens designed to combat 
obesity.14,18
Only a few rCTs have evaluated the impact of TS 
in patients with MetS and T2DM. By meta-analyzing 
available evidence, we found that TS was associ-
ated with a significant reduction of fasting glycemia, 
HOMA index, triglyceride levels and waist circum-
ference (WC) in patients with MetS.10 Correspond-
ingly, an improvement of fasting glycemia, HbA1c 
and triglyceride levels was observed in subjects with 
T2DM.10 To further understand the possible role of 
TS in body composition and glycometabolic profile 
in hypogonadal men, we more recently performed a 
meta-analysis of all rCTs comparing the effect of TS 
on different metabolic endpoints.63 Overall, 59 trials 
were included in the study enrolling 3029 and 2049 
subjects in the TS and control groups, respectively. 
no significant modification of body weight, WC and 
BMI was detected. However, TS was associated with 
follicle stimulating-hormone (FSH) and a reduction 
in estradiol. However, multiple regression analysis 
showed that the degree of body weight lost was the best 
determinant of total T rise (B=2.50±0.98, P=0.029), 
whereas no effect of estradiol decrease after weight 
loss on total T was observed.36 These data confirm 
that other fat-associated factors, besides estrogens, 
can be speculated as mediating obesity associated 
hypogonadism.
The increase in the amount of physical activity 
should be an essential component of the lifestyle 
modifications.45-49 According to World Health Orga-
nization recommendations (http://whqlibdoc.who.int/
publications/2010/9789241599979_eng.pdf) adults 
aged 18–64 years should do at least 150 minutes of 
moderate-intensity aerobic physical activity throughout 
the week, or at least 75 minutes of vigorous-intensity 
aerobic physical activity throughout the week, or an 
equivalent combination of moderate- and vigorous-
intensity activity. A recent meta-analysis including 47 
studies demonstrated that sedentary behavior in adults 
significantly increased the risk of all-cause mortality, 
CVD and cancer mortality and incidence as well as 
T2DM incidence.50 Interestingly, a recent randomized 
controlled trial (rCT) showed that resistance train-
ing might have an acute effect on T production and 
clearance rates, while the exercise-induced increases 
in serum T appeared to come about through decreased 
metabolic clearance rate of T.51
In line with what has been observed for all the 
aforementioned conditions, lifestyle modification 
and maintaining an active lifestyle in men resulted 
in improvement even in ED.52 A systematic review 
and meta-analysis of six rCTs evaluating the effect 
of lifestyle interventions and pharmacotherapy for 
CV on the severity of ED demonstrated an overall 
significant improvement in sexual function, which was 
confirmed even when only trials of lifestyle change 
interventions (n=4) were considered.53
Testosterone therapy
Despite previous evidence, it should be recognized 
that everyday clinical practice has shown that diet 
and behavioral therapies often ultimately fail. In fact, 
from 60% to 86% of weight lost is regained after 3 
years and 75%–121% after 5 years.54 A meta-analysis 
including 65 primary qualitative studies on the topic 
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a significant reduction of fat and with an increase of 
lean mass as well as with a reduction of fasting gly-
cemia and homeostasis model assessment (HOMA) 
index (Table 1). Similar results were observed for total 
cholesterol and triglyceride levels when only rCTs 
enrolling hypogonadal (total T<12 mol/L) subjects 
were considered (Table 1). Conversely, no improve-
ment in high density lipoprotein (HDL) cholesterol 
levels or in either systolic or diastolic blood pressure 
was observed (Table 1). In addition, the outcomes 
were better in younger individuals and in those with 
metabolic diseases.63 Finally, when the data were 
analyzed according to the type of T preparation used, 
no improvement in body composition (both lean and 
fat mass modification) and glycemic control was 
observed in those trials using oral T preparations, 
whereas the use of both transdermal and parenteral 
preparations were effective with the application of 
the latter drugs resulting in better outcomes.63 The 
observed improvement in glucose metabolism can 
be ascribed to either increased muscle mass or to 
decreased fat mass. However, our data suggest that 
increased muscle mass is most probably responsible 
for the more favorable glucose metabolism associated 
with TS. In fact, the positive associations between T 
levels, glycemia and HOMA-Ir index were confirmed 
in a multivariate model after adjusting for lean, but 
not fat, mass.63 Similarly, in an experimental model 
of MetS-associated hypogonadism, obtained by feed-
ing rabbits a high-fat diet, we demonstrated that T 
administration was able to dramatically reduce visceral 
adiposity and, in cultured adipocytes, to increase insulin 
sensitivity and triglyceride metabolism.43 Hence, our 
data show that TS might help hypogonadal individuals 
in changing body composition, glucose metabolism, 
and, possibly, weight. 
Considering the positive action of TS on body 
composition, and in particular on muscle mass and 
strength, it is possible that in established hypogonadal 
obese men, combining the effect of TS with lifestyle 
modifications could result in better outcomes. So far, 
five rCTs64-68 have specifically evaluated the effect 
of a combined therapy with TS and lifestyle modi-
fication on HG-associated metabolic derangements 
and body composition. Overall, the available rCTs 
enrolled 243 patients, with a mean follow-up of 36.8 
weeks. By meta-analyzing these subjects we recently 
reported that the combination of TS and lifestyle 
modifications is able to produce better outcomes than 
lifestyle behaviors alone, including the improvement 
of body composition (reduction of WC and fat mass 
and increase in lean mass), lipid profile (reduction of 
triglycerides levels), insulin resistance (reduction of 
insulin levels and HOMA index) and diastolic blood 
pressure (Table 2).18
TS and sexual function 
The effects of TS on male sexual functions in 
ED subjects are still very controversial.69,70 Another 
controversial issue is the effect of TS on phosphodies-
terase type 5 (PDE5) inhibitor (PDE5i) outcomes.70-72 
A substantial improvement in the response to PDE5is 
was seen in 37.5–92% of these men following a com-
bination of T therapy with PDE5is.70-72 However, data 
on placebo controlled rCTs are more conflicting.73-76 
We recently reported the largest, updated meta-
analysis evaluating the effect of TS on male sexual 
function and its synergism with the use of PDE5is in 
rCTs comparing the effect of TS vs. placebo or the 
Table 1. Mean difference or mean standardized differences in several 
clinical parameters after testosterone substitution as derived from 
meta-analysis of the available evidence (adapted from ref.# 63)
clinical parameter outcome
body composition
Weight (kg) 0.43 [-0.54; 1.39]
Body Mass Index (kg/m2) -0.66 [-2.66; 1.35]
Waist circumferences (cm) 0.25 [-0.09; 0.58]
Fat mass (standardised mean) -0.32 [-0.44; -0.19]**
Lean mass (standardised mean) 0.51 [0.37; 0.66]**
glucose profile
Fasting glycemia (mM) -0.34 [-0.51; -0.17]**
HOMA index -0.80 [-1.16; -0.45]**
Lipid profile
Total cholesterol (mM) -0.357 [-0.61; -0.13]**§
Triglycerides (mM) -0.22 [-0.37; -0.08]*§
HDL cholesterol (mM) -0.03 [-0.08; 0.01]
blood pressure
Systolic blood pressure (mmHg) 0.94 [-1.08; 2.96]
Diastolic blood pressure (mmHg) 0.95 [-0.66; 2.54]
*p<0.05, **p<0.0001; § only studies enrolling hypogonadal (total 
testosterone <12 nM) subjects were considered. HDL: high density 
lipoprotein; rCT: randomized controlled trial.
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effect of TS as an add-on to PDE5is.62 Overall, 41 
rCTs were included in the study, of which 29 com-
pared TS vs. placebo, while 12 trials evaluated the 
effect of TS as an add-on to PDE5is. Our data clearly 
indicated that TS is able to significantly ameliorate 
erectile function and to improve, in hypogonadal men 
(TT <12 nM), other aspects of male sexual response, 
including sexual desire and orgasm, as well as several 
other sexual parameters, including nocturnal erection, 
frequency of intercourse, overall sexual satisfaction 
and overall sexual function (Table 3).
Our study, however, was not able to clarify the 
role of TS as an add-on to PDE5is in the treatment 
of ED subjects. In fact, although a positive effect was 
observed in uncontrolled studies, the results were not 
confirmed when only rCTs were considered. The lack 
of benefits in rCTs may suggest the uselessness of 
TS as an adjunctive therapy to PDE5is in ED patients. 
However, it should be recognized that 3 out of 573-75 
of the aforementioned rCTs enrolled a population of 
mixed eugonadal/hypogonadal subjects at baseline. 
In addition, in Spitzer’s large trial,76 although only 
hypogonadal subjects were enrolled at baseline, TS 
was initiated after a sildenafil alone run-in period, 
leading to T increase up to the normal range (about 
12.0 nmol/L). Similarly, it has previously been reported 
that sexual inertia is associated with functional hypo-
gonadotropic hypogonadism which can be restored 
accompanied by improvement of sexual activity.77-81
concLusIon
Hypogonadism represents one of the several com-
plications of obesity and T2DM in men. In these men, 
hypogonadism can further worsen the metabolic profile 
and increase abdominal fat. Sexual symptoms are 
the most specific symptoms associated with hypog-
onadism in aging men. Although hypogonadism can 
exacerbate obesity-associated ED, recent data suggest 
that a direct contribution of fat derived factors could 
be hypothesized. Lifestyle modifications and weight 
loss are the first steps for ED patients with obesity or 
metabolic diseases. In symptomatic hypogonadal men 
with metabolic impairment and obesity, combining 
the effect of testosterone substitution with lifestyle 
modifications could result in better outcomes.
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